PMID- 26771865
OWN - NLM
STAT- MEDLINE
DCOM- 20160816
LR  - 20160406
IS  - 1473-5741 (Electronic)
IS  - 0959-4973 (Linking)
VI  - 27
IP  - 5
DP  - 2016 Jun
TI  - Efficacy and safety analysis of chemotherapy for advanced colitis-associated 
      colorectal cancer in Japan.
PG  - 457-63
LID - 10.1097/CAD.0000000000000338 [doi]
AB  - Chemotherapy for advanced colitis-associated colorectal cancer (CAC) has been 
      insufficiently evaluated. The goal of this study was to clarify the efficacy and 
      safety of chemotherapy for CAC in Japan. CAC patients who were treated with 
      chemotherapy between 2005 and 2015 were retrospectively examined. Twenty-nine 
      patients (median age, 48 years; 23 men) were assessed. Eighteen patients had 
      ulcerative colitis, and 11 had Crohn's disease. Three ulcerative colitis and four 
      Crohn's disease patients were in the active disease phase. Primary tumors were 
      located in the rectum/anus (n=16), the left colon (n=9), or the right colon 
      (n=4). Palliative or adjuvant chemotherapy was performed in 13 and 16 patients, 
      respectively. First-line palliative chemotherapy regimens were as follows: 
      fluorouracil, leucovorin, and oxaliplatin (FOLFOX; n=6), FOLFOX+bevacizumab 
      (n=3), and others (n=4). Adjuvant chemotherapy regimens were S-1 (n=7), 
      oxaliplatin-based (n=4) and others (n=5). In palliative chemotherapy, the 
      objective response rate was 15%, and the median progression-free survival and 
      overall survival were 182 and 315 days, respectively. In adjuvant chemotherapy, 
      the 5-year relapse-free survival rate was 78%. Grade 3/4 adverse events (AEs) 
      were observed in 16 patients (55%). Active and remission inflammatory bowel 
      disease patients suffered grade 3/4 nonhematological AEs at an incidence of 71 
      and 23%, respectively (P<0.01). Dose reduction was required in 11 patients (38%), 
      eight of whom required it for hematological AEs. Adjuvant chemotherapy for CAC 
      exhibited sufficient efficacy, whereas modest efficacy was shown for palliative 
      chemotherapy for CAC. AEs, particularly nonhematological AEs, were closely 
      associated with disease activity of colitis.
FAU - Nio, Kenta
AU  - Nio K
AD  - aDepartment of Medicine and Biosystemic Science, Kyushu University Graduate 
      School of Medical Sciences bDepartment of Surgery, Fukuoka University Chikushi 
      Hospital cDepartment of Comprehensive Clinical Oncology, Faculty of Medical 
      Sciences, Kyushu University dDepartment of Gastrointestinal and Medical Oncology, 
      National Kyushu Cancer Center Departments of eMedicine and Clinical Science 
      fSurgery and Oncology gAnatomical Pathology, Pathological Sciences, Graduate 
      School of Medical Sciences, Kyushu University hDepartment of Oncology, 
      Hamanomachi Hospital, Fukuoka iFirst Department of Internal Medicine, Faculty of 
      Medicine, University of Miyazaki Hospital jDepartment of Chemotherapy, Miyazaki 
      Prefectural Miyazaki Hospital, Miyazaki, Japan.
FAU - Higashi, Daijiro
AU  - Higashi D
FAU - Kumagai, Hozumi
AU  - Kumagai H
FAU - Arita, Shuji
AU  - Arita S
FAU - Shirakawa, Tsuyoshi
AU  - Shirakawa T
FAU - Nakashima, Koji
AU  - Nakashima K
FAU - Shibata, Yoshihiro
AU  - Shibata Y
FAU - Esaki, Motohiro
AU  - Esaki M
FAU - Manabe, Tatsuya
AU  - Manabe T
FAU - Nagai, Shuntaro
AU  - Nagai S
FAU - Ueki, Takashi
AU  - Ueki T
FAU - Nakano, Michitaka
AU  - Nakano M
FAU - Ariyama, Hiroshi
AU  - Ariyama H
FAU - Kusaba, Hitoshi
AU  - Kusaba H
FAU - Hirahashi, Minako
AU  - Hirahashi M
FAU - Oda, Yoshinao
AU  - Oda Y
FAU - Esaki, Taito
AU  - Esaki T
FAU - Mitsugi, Kenji
AU  - Mitsugi K
FAU - Futami, Kitaro
AU  - Futami K
FAU - Akashi, Koichi
AU  - Akashi K
FAU - Baba, Eishi
AU  - Baba E
LA  - eng
PT  - Journal Article
PT  - Multicenter Study
PL  - England
TA  - Anticancer Drugs
JT  - Anti-cancer drugs
JID - 9100823
SB  - IM
MH  - Adult
MH  - Aged
MH  - Antineoplastic Combined Chemotherapy Protocols/adverse effects/*therapeutic use
MH  - Chemotherapy, Adjuvant
MH  - Colitis/complications/*drug therapy
MH  - Colorectal Neoplasms/*drug therapy/etiology/pathology
MH  - Disease-Free Survival
MH  - Female
MH  - Humans
MH  - Inflammatory Bowel Diseases/complications/*drug therapy
MH  - Male
MH  - Middle Aged
MH  - Neoplasm Metastasis
MH  - Neoplasm Recurrence, Local
MH  - Retrospective Studies
EDAT- 2016/01/16 06:00
MHDA- 2016/08/17 06:00
CRDT- 2016/01/16 06:00
PHST- 2016/01/16 06:00 [entrez]
PHST- 2016/01/16 06:00 [pubmed]
PHST- 2016/08/17 06:00 [medline]
AID - 10.1097/CAD.0000000000000338 [doi]
PST - ppublish
SO  - Anticancer Drugs. 2016 Jun;27(5):457-63. doi: 10.1097/CAD.0000000000000338.